Stock Watch: Pfizer Pushed And Pulled By Pandemic Products
Inverse Correlation Of Pfizer’s Quarterly COVID-19 Vaccine And Antiviral Sales
With Pfizer expecting significant pandemic-related sales out to at least 2026, the difficulty forecasting those sales and inventory work-down resulted in stock price volatility.
You may also be interested in...
GSK Exceeded Expectations In 2022, Now Looking For Edge Over Pfizer In RSV Battle
Having outperformed in 2022, GSK is gearing up for key regulatory and market access decisions on its RSV vaccine, but is confident it holds superior data compared with rival Pfizer.
Stock Watch: The Transatlantic Asymmetries Of Generic Drugs
Investors love an opportunity to invest in a recovery play after the disclosure of bad news but, having lived in recent years under a succession of clouds, will generic drug companies begin to see biosimilars resurrect their sales growth?
Stock Watch: Funding Biotech In A Hostile Environment
When the traditional fundraising window closes and clinical, regulatory or commercial success eludes, other routes to raise cash emerge. But these have also become more scarce recently, leaving all-stock consolidations.